Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Round 2 starting - .0015 back up.... Tim
Closed at .0007 with the ask getting spanked. Tim
Nice Close at HOD - looking forward to Monday..... Tim
Luna Technologies Launches New Optical Vector Analyzer
Luna Technologies, an industry-leading developer of advanced solutions for fiber optic test and measurement systems and a division of Luna Innovations Incorporated (NASDAQ: LUNA), today announced its newest product in the Optical Vector Analyzer™ platform, the OVA 5000. This instrument is the fastest, most accurate and economical tool for loss, dispersion and polarization measurements of modern optical networking equipment, all packaged with a user-friendly interface and a small footprint. It is the ideal device for single-measurement, all-parameter analysis of fiber optic components and assemblies up to 150 meters in length. With the new OVA 5000, a full C and L band characterization of all linear optical parameters can be completed in less than three seconds.
Luna’s patented characterization technique uses swept-wavelength interferometry to accurately measure all device characteristics in a single scan of a tunable laser. The OVA is the only instrument measuring the complete linear transfer function of a device under test. With this measurement, the OVA characterizes all linear optical parameters including: Insertion Loss (IL), Polarization Dependent Loss (PDL), Group Delay (GD), Chromatic Dispersion (CD), Polarization Mode Dispersion (PMD), and Second Order PMD. It also measures the Optical Time Domain Response, the complex Jones Matrix Elements and the Optical Phase Response.
“We offer a unique and unprecedented way of characterizing optical components that provides our customers with valuable benefits,” said Luna’s Chief Technology Officer Dr. Mark Froggatt. “Speed is incredibly important, which is where Luna has an edge. The OVA 5000 offers complete, rapid, single-scan measurement of all parameters in real-time which allows our DWDM component manufacturers to save time and money.”
Luna’s OVA 5000 is available within six to eight weeks from order placement. For more information email the Luna sales team at solutions@lunatechnologies.com, or see the Web site at www.lunatechnologies.com for the list of domestic and international contacts. Luna will be demonstrating its optical test and measurement solutions at the European Conference and Exhibition on Optical Communications (ECOC) in booth #309, beginning September 20 in Vienna, Austria.
About Luna Technologies:
Luna Technologies, a division of Luna Innovations Incorporated located in Blacksburg, Virginia, manufactures and markets test and measurement equipment and integrated sensing solutions. Luna Technologies' products are used for test, measurement and sensing in telecommunications, manufacturing, power generation and distribution, down-hole oil and gas, aerospace, and defense applications. Its products award-winning products are sold and distributed throughout North America, Europe, the Middle East and Asia.
Forward Looking Statements:
This release includes information that constitutes “forward-looking statements” made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements regarding the benefits and performance of Luna’s OVA. Statements that describe the company’s business strategy, goals, prospects, opportunities, outlook, plans or intentions are also forward looking statements. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including technical difficulties and the failure of Luna’s OVA to perform and risks and uncertainties set forth in the company’s periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC’s website at http://www.sec.gov, and at the company’s website at http://www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6052586&lang=en
AS/OS are both still at 390M I believe. Tim
AERN - .0038 X .0042. Could go here, real thin. Tim
AERN - .003 X .0036. Tim
AERN - .0026, plus 85%. 25M O/S getting some action, B/A .0026X.0027. Moves on air..... Tim
Nice start today for VRNM(D) - up 48 cents or so already. Tim
Agreed - took me awhile to fill at the ask this week also - thin... Tim
AERN - first post here on this board in 3 and a half years. Up 50% at .0021. 25 million O/S. Tim
They did the R/S primarily to ensure compliance with NASDAQ listing requirements of over a buck a share. IMO this is a great long term hold. Tim
AERN - no volume yet but Bid/Ask back to .0018X.0019, last .0014. Extremely Thin... Tim
If you haven't already done so - add a "D" to the end of the ticker, ie: VRNMD. Tim
Great post - I could not agree more as it is all about the share structure on the triples Os.
BTW, for those yelling dilution I doubt that is a major issue at this point either. The company would have simply dropping them at the bid yesterday (.0001) and there would have been no up tick. Plus no fluff PR to dilute into.
Tim
Was talking at .0001 (Bid). Have not seen any small numbers at .0002 (Ask). Tim
Probably just partials - it gave me just 300 on the bid awhile back. Tim
TECA - ask U/T to .0002.......
TECA - big volume coming in - somebody front loading looks like. Tim
OT: The list changes very often with Scottrade. On this week, off the next, has been my experience. Tim
VRNM 1 for 12 R/S effective after close today:
Verenium Announces Reverse Stock Split to Take Effect September 9
CAMBRIDGE, Mass., Sept. 8 /PRNewswire-FirstCall/ -- Verenium Corporation (NASDAQ:VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced that the previously announced 1-for-12 reverse stock split of the Company's common stock will take effect after market close on Wednesday, September 9, 2009. Verenium's shares will continue to trade on the NASDAQ Global Market under the symbol VRNM. A new CUSIP number will be assigned to Verenium's common stock when the split becomes effective.
The 1-for-12 reverse stock split will automatically convert 12 shares of the Company's common stock into one share of common stock, reducing the number of shares of the Company's common stock outstanding from approximately 111.3 million as of the filing of the Company's most recent Quarterly Report on Form 10-Q, to approximately 9.3 million shares. Shares of the Company's common stock, underlying stock options, warrants and convertible debt instruments that are outstanding immediately prior to the effective date of the reverse stock split will be affected proportionately. Cash will be paid in lieu of any fractional shares resulting from the reverse stock split.
Verenium's transfer agent, American Stock Transfer, is the exchange agent for the reverse split and will distribute a letter of transmittal to record holders with instructions for the surrender of old stock certificates. For beneficial holders of pre-reverse split shares, the brokerage firm where the beneficial shares are held will make the appropriate adjustment to the number of shares held following the effective date of the reverse split.
About Verenium
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through a joint venture with BP, the Company is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com/.
Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to the Company's strengthening of its balance sheet and the impact on the exchange on future growth and success, the Company's financing flexibility or ability to obtain future financing, operations, capabilities, commercialization activities, target markets, cellulosic ethanol facilities, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's technologies, risks associated with the costs, labor requirements and labor availability associated with Verenium's demonstration plant, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic ethanol and other biofuels and the commercial prospects of those industries, Verenium's dependence on existing collaboration, manufacturing, and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, changes in the U.S. or global energy markets and laws and regulations applicable to them, and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year ended December 31, 2008 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these forward-looking statements.
Verenium Contacts:
Kelly Lindenboom Sarah Carmody Vice President, Sr. Corporate Corporate Communications Communications Associate 617-674-5335 617-674-5357
DATASOURCE: Verenium Corporation
CONTACT: Kelly Lindenboom, Vice President, Corporate Communications,
+1-617-674-5335, , or Sarah Carmody, Sr.
Corporate Communications Associate, +1-617-674-5357,
, both of Verenium Corporation
Web Site: http://www.verenium.com/
Ask went from .0031 to .0047 yesterday so not bad. Tim
Yeap, and nice to see the bid holding up at .005 all day. Tim
Actually bought at .0001 and now holding alot of freebies long. Like I said depends on your perspective. Tim
Depends on your perspective I guess - you could also look at it as up 100% from where it started yesterday morning.
Reference:
.0004 down 33%, small volume, geez it's not like I didn't say this was going to happen today. I sure hope people got out yesterday. Going to get a lot worse before the day is over.
ECGR - Ask getting pounded, now .002X.0024, up 122%. Tim
ECGR going now.... Tim
I actually like it on this one. Think it may dip a little initially but than could go back up hard with the new low O/S. If it dips low I'll add. Can't compare these to pink R/Ss. Tim
Verenium Reports Results of 2009 Annual Stockholders Meeting
Wednesday 09/02/2009 4:49 PM ET - Pr Newswire
As of 12:00 AM ET 9/2/09
Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today reported that at the Company's annual meeting of stockholders held on Tuesday, September 1st in Cambridge, MA, each of the following proposals were approved:
-- Election of the three (3) directors - Dr. James H. Cavanaugh, Mr. Simon
Rich, and Mr. Joshua Ruch - to hold office until the 2012 Annual Meeting
of Stockholders;
-- Approval to effect a reverse stock split at any exchange ratio from
1-for-12 to 1-for-20;
-- Approval of a stock option exchange program; and
-- Ratification of the appointment of Ernst & Young LLP as the
Company's independent registered public accounting firm for the
fiscal year ending December 31, 2009.
In addition, the Company's Board of Directors today approved a 1-for-12 reverse stock split of the Company's common stock and set September 2, 2009 as the record date for the reverse split. The 1-for-12 reverse stock split will automatically convert 12 shares of the Company's common stock into one share of common stock. The reverse stock split will reduce the number of shares of the Company's common stock outstanding from approximately 111.3 million as of the filing of the Company's most recent Quarterly Report on Form 10-Q, to approximately 9.3 million shares, and will also affect all issued and outstanding shares of the Company's common stock, and shares of common stock underlying stock options and warrants that are outstanding immediately prior to the effective date of the reverse stock split. Cash will be paid in lieu of any fractional shares resulting from the reverse stock split.
"We are pleased with the results of our annual meeting and thank our shareholders for their continued support," said Carlos A. Riva, President and Chief Executive Officer at Verenium. "Verenium has undergone substantial changes over the past year and with well over 100 million shares currently outstanding, we believe a reverse stock split is an important and necessary change in our financial structure."
"Additionally, we believe that the reverse stock split is a necessary step to ensure our continued compliance with NASDAQ listing requirements and could also allow us to attract a broader range of eligible investors to our story," added James E. Levine, Executive Vice President and Chief Financial Officer of Verenium.
Approximately 83% of outstanding shares entitled to vote were represented at the meeting. The complete results of the voting will be included in the next quarterly report on Form 10-Q to be filed by the Company with the Securities and Exchange Commission.
About Verenium
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through a joint venture with BP, the Company is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to the Company's strengthening of its balance sheet and the impact on the exchange on future growth and success, the Company's financing flexibility or ability to obtain future financing, operations, capabilities, commercialization activities, target markets, cellulosic ethanol facilities, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's technologies, risks associated with the costs, labor requirements and labor availability associated with Verenium's demonstration plant, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic ethanol and other biofuels and the commercial prospects of those industries, Verenium's dependence on existing collaboration, manufacturing, and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, changes in the U.S. or global energy markets and laws and regulations applicable to them, and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year ended December 31, 2008 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these forward-looking statements.
Verenium Contacts:
Kelly Lindenboom Sarah Carmody
Vice President, Corporate Sr. Corporate Communications Associate
Communications
617-674-5335 617-674-5357
kelly.lindenboom@verenium.com sarah.carmody@verenium.com
SOURCE Verenium Corporation
Sounds good - I'm holding a boat load of freebies long. Tim
At the ask too - wonder who is loading for a run... Tim
Did the T/A happen to also provide the current O/S and Float? Tim
Think you are watching CENC NOT CINT... Tim
Huhh, .0007X.00008.
MLHP - Keep an eye on it, might be go time. Last is .0004 with bid/ask at .0006X.0007. A/S Maxed below 500M. Tim
Edit: Soebody just tapped it for .00007 (up 133%).
Headed that way - shake over, .0014 back up. Tim
CINT - round two starting. Shake appears to be over. Tim
CINT - 5s getting hammered, 6s up... Tim
CINT - Ask slapping... Tim
SARO - Adding.... Tim
You don't really beieve that I hope? Only 6 million volume and ask is same as close yesterday (.0007). Tim